Table of Contents

company-logo

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.

Immunotech Biopharm Dividend Announcement

• Immunotech Biopharm does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Immunotech Biopharm dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Immunotech Biopharm Dividend History

Immunotech Biopharm Dividend Yield

Immunotech Biopharm current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Immunotech Biopharm stock? Use our calculator to estimate your expected dividend yield:

Immunotech Biopharm Financial Ratios

P/E ratio-2987.58
PEG ratio142.58
P/B ratio11.39
ROE-0.24%
Payout ratio0.00%
Current ratio0.38
Quick ratio0.36
Cash Ratio0.17

Immunotech Biopharm Dividend FAQ

Does Immunotech Biopharm stock pay dividends?
Immunotech Biopharm does not currently pay dividends to its shareholders.
Has Immunotech Biopharm ever paid a dividend?
No, Immunotech Biopharm has no a history of paying dividends to its shareholders. Immunotech Biopharm is not known for its dividend payments.
Why doesn't Immunotech Biopharm pay dividends?
There are several potential reasons why Immunotech Biopharm would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Immunotech Biopharm ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Immunotech Biopharm has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Immunotech Biopharm a dividend aristocrat?
Immunotech Biopharm is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Immunotech Biopharm a dividend king?
Immunotech Biopharm is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Immunotech Biopharm a dividend stock?
No, Immunotech Biopharm is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Immunotech Biopharm stocks?
To buy Immunotech Biopharm you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Immunotech Biopharm stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.